New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
05:47 EDTSTJSt. Jude Medical announces preliminary results from EnligHTN III study
St. Jude Medical announced preliminary results from the EnligHTN III study, which found the company’s second-generation EnligHTN renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. Results from the EnligHTN I, II and III trials presented during EuroPCR add to the growing body of clinical evidence supporting the benefits of EnligHTN renal denervation technologies.
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
10:02 EDTSTJOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:57 EDTSTJSt. Jude Medical initiated with a Strong Buy at Needham
Subscribe for More Information
September 23, 2014
09:45 EDTSTJLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy discusses the ultimate market opportunity for leadless pacers and compares Medtronic vs St. Jude Medical on an Analyst/Industry conference call to be held on September 24 at 2 pm.
September 22, 2014
08:32 EDTSTJSt. Jude receives CE Mark approval of Tendril STS, IsoFlex Optim labeling
Subscribe for More Information
06:51 EDTSTJSt. Jude Medical recent weakness a buying opportunity, says Barclays
Barclays said St. Jude Medical weakness is a buying opportunity. The analyst said CardioMEMS is underappreciated by the Street and valuation compelling given sequential revenue growth. Shares are Overweight rated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use